Literature DB >> 17498805

Incidence of uveal melanoma in Europe.

Gianni Virgili1, Gemma Gatta, Laura Ciccolallo, Riccardo Capocaccia, Annibale Biggeri, Emanuele Crocetti, Jean-Michel Lutz, Eugenio Paci.   

Abstract

PURPOSE: To estimate incidence rates of uveal melanoma in Europe from 1983 to 1994.
DESIGN: Incidence analysis of data from cancer registries adhering to the European Cancer Registry-based study on survival and care of cancer patients (EUROCARE) (cases diagnosed from 1983 to 1994). PARTICIPANTS: Data of 6673 patients with ocular melanoma (as defined by International Classification of Diseases for Oncology morphology codes 8720 to 8780 [melanoma] and International Classification of Diseases 9 (ICD9) codes 190.0 [iris and ciliary body], 190.5 [retina], 190.6 [choroid], and 190.9 [unspecified ocular location]) from 33 cancer registries of 16 European countries.
METHODS: Incidence rate ratios (IRRs) were obtained from a multilevel Poisson regression model. MAIN OUTCOME MEASURES: Incidence rates and IRRs associated with demographic and geographic variables.
RESULTS: Standardized incidence rates increased from south to north across registries, from a minimum of <2 per million in registries of Spain and southern Italy up to >8 per million in Norway and Denmark. The inclusion of tumors with unspecified ocular location (code 190.9) increased incidence rates in most United Kingdom registries, but not in the other geographic areas, where this code was seldom used for uveal melanomas. Incidence increased noticeably up to age 55 (IRR, 1.46 per 5 years; 95% confidence interval [CI], 1.36-1.57) but leveled off after age 75 (IRR, 0.99 per 5 years; 95% CI, 0.93-1.05), with intermediate levels midway (IRR, 1.18 per 5 years; 95% CI, 1.12-1.23). It was also higher in males (IRR, 1.22; 95% CI, 1.16-1.28). Rates were stable during the study period, but a cohort effect was evidenced, accounting for higher incidence rates in people born during the period 1910 to 1935 (P = 0.005). Incidence increased with latitude (P = 0.008), which explained most differences in rates among areas.
CONCLUSIONS: In this large series of uveal melanomas, we found stable incidence during the years 1983 to 1994. The north-to-south decreasing gradient supports the protective role of ocular pigmentation. European ophthalmologists should develop guidelines to standardize the coding of tumors treated conservatively using the ICD classification to improve the registration and surveillance of uveal melanoma by cancer registries.

Entities:  

Mesh:

Year:  2007        PMID: 17498805     DOI: 10.1016/j.ophtha.2007.01.032

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  118 in total

1.  Jejunojejunal intussusception secondary to metastatic uveal melanoma after 11 years of remission.

Authors:  Hifza Waheed Butt; Sarthak Soin; Faisal Ali; Antoni Wojtkowski
Journal:  BMJ Case Rep       Date:  2019-06-22

2.  Uveal melanoma cell growth is inhibited by aminoimidazole carboxamide ribonucleotide (AICAR) partially through activation of AMP-dependent kinase.

Authors:  Ahmad Al-Moujahed; Fotini Nicolaou; Katarzyna Brodowska; Thanos D Papakostas; Anna Marmalidou; Bruce R Ksander; Joan W Miller; Evangelos Gragoudas; Demetrios G Vavvas
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-29       Impact factor: 4.799

3.  3D WrapTM Ultra-Widefield Reconstruction in Stereotactic Radiosurgery for Choroidal Melanoma.

Authors:  Maria Vittoria Cicinelli; Alessandro Marchese; Francesco Bandello; Giulio Maria Modorati
Journal:  Ocul Oncol Pathol       Date:  2019-06-12

4.  Iris color and associated pathological ocular complications: a review of epidemiologic studies.

Authors:  Hong-Peng Sun; Yi Lin; Chen-Wei Pan
Journal:  Int J Ophthalmol       Date:  2014-10-18       Impact factor: 1.779

5.  Intraprocedural 3D perfusion measurement during chemoembolisation with doxorubicin-eluting beads in liver metastases of malignant melanoma.

Authors:  Philippe L Pereira; Kristina Krüger; Ernst Hohenstein; Florian Welke; Christof Sommer; Friedegund Meier; Thomas Eigentler; Claus Garbe
Journal:  Eur Radiol       Date:  2017-11-09       Impact factor: 5.315

6.  Atypical activation of the G protein Gαq by the oncogenic mutation Q209P.

Authors:  Marcin Maziarz; Anthony Leyme; Arthur Marivin; Alex Luebbers; Prachi P Patel; Zhe Chen; Stephen R Sprang; Mikel Garcia-Marcos
Journal:  J Biol Chem       Date:  2018-10-23       Impact factor: 5.157

7.  A case-control study: occupational cooking and the risk of uveal melanoma.

Authors:  Andrea Schmidt-Pokrzywniak; Karl-Heinz Jöckel; Anja Marr; Norbert Bornfeld; Andreas Stang
Journal:  BMC Ophthalmol       Date:  2010-10-22       Impact factor: 2.209

8.  Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma.

Authors:  K Strobel; B Bode; R Dummer; P Veit-Haibach; D R Fischer; L Imhof; S Goldinger; Hans C Steinert; G K von Schulthess
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06-04       Impact factor: 9.236

Review 9.  Tumor Characteristics, Genetics, Management, and the Risk of Metastasis in Uveal Melanoma.

Authors:  Erin E Nichols; Ann Richmond; Anthony B Daniels
Journal:  Semin Ophthalmol       Date:  2016-04-29       Impact factor: 1.975

Review 10.  Disparities in Uveal Melanoma: Patient Characteristics.

Authors:  Erin E Nichols; Ann Richmond; Anthony B Daniels
Journal:  Semin Ophthalmol       Date:  2016-04-29       Impact factor: 1.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.